

knowledge of local, State, and Federal housing programs and how they can be accessed; or

ii. Short-term or emergency housing defined as necessary to gain or maintain access to medical care and must be related to either:

a. Housing services that include some type of medical or supportive service: including, but not limited to, residential substance abuse or mental health services (not including facilities classified as an Institute of Mental Diseases under Medicaid), residential foster care, and assisted living residential services; or

b. Housing services that do not provide direct medical or supportive services, but are essential for an individual or family to gain or maintain access and compliance with HIV-related medical care and treatment. Necessity of housing services for purposes of medical care must be certified or documented.

B. Short-term or emergency assistance is understood as transitional in nature and for purposes of moving or maintaining an individual or family in a long-term, stable living situation. Thus, such assistance cannot be permanent and must be accompanied by a strategy to identify, relocate, and/or ensure the individual or family is moved to, or capable of maintaining, a long-term, stable living situation.

C. Housing funds cannot be in the form of direct cash payments to recipients for services and cannot be used for mortgage payments.

D. The Ryan White HIV/AIDS Program must be the payer of last resort. In addition, funds received under the Ryan White HIV/AIDS Program must be used to supplement, but not supplant funds currently being used from local, State, and Federal Agency programs. Grantees must be capable of providing HAB with documentation related to the use of funds as the payer of last resort and the coordination of such funds with other local, State, and Federal funds.

E. Housing-related expenses are limited to Parts A, B, and D of the Ryan White HIV/AIDS Program, and are not allowable expenses under Part C.

Dated: February 5, 2010.

Mary K. Wakefield,
Administrator.

[FR Doc. 2010-2926 Filed 2-9-10; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Expert Meeting on Measurement Criteria for Children's Health Insurance Program; Reauthorization Act Pediatric Quality Measures

AGENCY: Agency for Healthcare Research and Quality (AHRQ).

ACTION: Notice of public meeting.

SUMMARY: This notice announces a meeting to identify measurement criteria for use in carrying out the Pediatric Quality Measures Program (PQMP) under Section 1139A(b) of the Social Security Act as enacted in the Children's Health Insurance Program Reauthorization Act (CHIPRA).

DATES: The meeting will be held on Wednesday, February 24, 2010, from 10 a.m. to 5 p.m. and Thursday, February 25, 2010, from 8 a.m. to 4 p.m.

ADDRESSES: Agency for Healthcare Research and Quality Eisenberg Building, 540 Gaither Rd., Rockville, MD 20850 and by public webcast.

FOR FURTHER INFORMATION CONTACT: Maushami DeSoto, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland 20850, (301) 427-1546. For press-related information, please contact Karen Migdail at (301) 427-1855.

If sign language interpretation or other reasonable accommodation for a disability is needed, please contact Mr. Michael Chew, Director, Office of Equal Employment Opportunity Program, Program Support Center, on (301) 443-1144, no later than February 20, 2010.

SUPPLEMENTARY INFORMATION:

I. Purpose

In early 2009, CHIPRA (Pub. L. 111-3) reauthorized the Child Health Insurance Program (CHIP) originally established in 1997, and in Title IV of the law, added a number of new provisions designed to improve health care quality and outcomes for children. AHRQ is working closely with the Centers for Medicare and Medicaid Services (CMS) and the CHIPRA Federal Quality Workgroup in implementing these provisions. For more information about AHRQ's role in carrying out the quality provisions of CHIPRA, and for a list of an initial core set of children's healthcare quality measures voluntary use by Medicaid programs and Children's Health Insurance Programs and the health plans and providers of care that the programs engage with, mandated by the Act, that has been

identified and posted for public comment, see <http://www.ahrq.gov/chip/chipraact.htm>.

CHIPRA further directed the Secretary to establish a Pediatric Quality Measures Program (PQMP) to strengthen and expand the initial core measure set required under its section 401(a). The statutory goal of the PQMP is to produce an improved core set of children's healthcare quality measures for use by public and private programs, health insurers, providers and patients, by January 1, 2013. In order to achieve this goal, measurement criteria to develop and enhance pediatric health care measures need to be identified and framed for use by those who will be developing and enhancing the measures under the PQMP. The PQMP objectives are to: Expand, improve and strengthen the initial core measure set and existing pediatric measures used by public and private health care purchasers and advance the development of new and emerging quality measures; and thereby, increase the portfolio of evidence-based and consensus-based, pediatric quality measures available to public and private purchasers of children's health care services, providers, and consumers as well as for use by policymakers at all political levels, including use in mandated reports to Congress on voluntary State reporting and on any need for further legislation.

In accordance with statutory requirements, the measures to be developed or enhanced under this program will cover a range of pediatric preventive services, treatments and services for both acute and chronic conditions, including health services to correct or ameliorate the effects of physical and mental conditions; and health services to aid in the growth and development of children with special health care needs; and measure and duration of health care coverage. Said measures are to be designed to ensure that data collected are comparable at the State, health plan and provider levels, risk-adjusted if appropriate, and periodically updated. In addition, pursuant to section 401(s) of CHIPRA, measures are to be able to identify disparities by race and ethnicity, socioeconomic status, and special healthcare needs.

II. Agenda

On Wednesday, February 24, 2010, the meeting will convene at 10 a.m. The meeting will focus on engaging invited experts and public participants in identifying criteria for pediatric quality measures to be used by PQMP grant and contract program awardees beginning in September 2010. The agenda will cover

discussions of key measure criteria in existence and participants will be asked to identify criteria suitable for the measure development and enhancement work to be supported by the PQMP program.

A more specific proposed agenda and instructions for public access to the meeting will be posted before the meeting at <http://www.ahrg.gov/chip/chipraact.htm>. The final agenda, including the time for public comment during the meeting, will be available on the AHRQ Web site at <http://www.ahrg.gov/chip/chipraact.htm> no later than February 14, 2010. A transcript of the meeting will be available within 21 business days after the meeting.

Dated: February 2, 2010.

Carolyn M. Clancy,
Director.

[FR Doc. 2010-2873 Filed 2-9-10; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, February 25, 2010, 1 p.m. to February 25, 2010, 4 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on February 1, 2010, 75 FR 5092.

The meeting will be held February 22, 2010, from 11 a.m. to 2 p.m. The meeting location remains the same.

The meeting is closed to the public.

Dated: February 2, 2010.

Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-2886 Filed 2-9-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Auditory, Pain and Chemosensation.

Date: March 1-2, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting)

Contact Person: Lynn E. Luethke, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5166, MSC 7844, Bethesda, MD 20892, (301) 806-3323, luethkel@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Small Business: Drug Discovery and Development.

Date: March 1-2, 2010.

Time: 8:30 a.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Sergei Ruvinov, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892. 301-435-1180. ruvinser@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Microvascular Interactions.

Date: March 3, 2010.

Time: 3 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call)

Contact Person: Manjit Hanspal, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7804, Bethesda, MD 20892, 301-435-1195, hanspalm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Fellowship: Chemical and Bioanalytical Sciences.

Date: March 4, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Denise Beusen, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142,

MSC 7806, Bethesda, MD 20892, (301) 435-1267, beusend@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Topics in Cancer Research.

Date: March 8-9, 2010.

Time: 10 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting)

Contact Person: Eun Ah Cho, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, (301) 451-4467, choe@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Program Project: National Radiotracer Resource Center.

Date: March 14-16, 2010.

Time: 6 p.m. to 1 p.m.

Agenda: To review and evaluate grant applications.

Place: The Parkway Hotel, 4550 Forest Park Avenue, St. Louis, MO 63108.

Contact Person: Keith Crutcher, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, MSC 7846, Bethesda, MD 20892, 301-435-1278, crutcherka@csr.nih.gov.

Name of Committee: AIDS and Related Research Integrated Review Group, Behavioral and Social Consequences of HIV/AIDS Study Section.

Date: March 15-16, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Marina del Rey Marriott, 4100 Admiralty Way, Marina del Rey, CA 90292.

Contact Person: Mark P. Rubert, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301-806-6596, rubertm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, PAR Panel: Cancer Health Disparities.

Date: March 15-16, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hotel Monaco, 700 F Street, NW., Washington, DC 20001.

Contact Person: Nywana Sizemore, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6204, MSC 7804, Bethesda, MD 20892, 301-435-1718, sizemoren@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: CDIN and CNN Member Applications II.

Date: March 15, 2010.

Time: 11 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call)